ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone218-634-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$201.58 million
Profitability
Miscellaneous
Employees299
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions
What is ANI Pharmaceuticals' stock symbol?
ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."
How were ANI Pharmaceuticals' earnings last quarter?
ANI Pharmaceuticals Inc (NASDAQ:ANIP) issued its quarterly earnings data on Wednesday, August, 7th. The specialty pharmaceutical company reported $1.44 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.18 by $0.26. The specialty pharmaceutical company had revenue of $54.36 million for the quarter, compared to analysts' expectations of $55.20 million. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The firm's revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.13 earnings per share. View ANI Pharmaceuticals' Earnings History.
When is ANI Pharmaceuticals' next earnings date?
What guidance has ANI Pharmaceuticals issued on next quarter's earnings?
ANI Pharmaceuticals updated its FY19 earnings guidance on Wednesday, August, 7th. The company provided earnings per share guidance of $5.57-6.21 for the period, compared to the Thomson Reuters consensus estimate of $6.01. The company issued revenue guidance of $220-226 million, compared to the consensus revenue estimate of $239.80 million.
What price target have analysts set for ANIP?
3 brokers have issued 12-month price objectives for ANI Pharmaceuticals' shares. Their forecasts range from $82.00 to $90.00. On average, they expect ANI Pharmaceuticals' stock price to reach $87.00 in the next year. This suggests a possible upside of 34.5% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals.
What is the consensus analysts' recommendation for ANI Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals.
What are Wall Street analysts saying about ANI Pharmaceuticals stock?
Here are some recent quotes from research analysts about ANI Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (8/19/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post 1Q19, we are reiterating our Overweight rating and raising our 12-month price target to $89 from $74. The company continues to advance its potentially transformational corticotropin product, and has committed to an sNDA filing goal of 1Q2020, while continuing to deliver strong top line growth. If ANIP is successful in gaining approval for this product, and is able to capture a small portion of the Acthar market, we estimate this could result in an additional $150MM+ in revenue for the company. For context, the midpoint of the company’s 2019 revenue guidance is $238MM." (5/9/2019)
Has ANI Pharmaceuticals been receiving favorable news coverage?
Media headlines about ANIP stock have been trending positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ANI Pharmaceuticals earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for ANI Pharmaceuticals.
Are investors shorting ANI Pharmaceuticals?
ANI Pharmaceuticals saw a increase in short interest in July. As of July 31st, there was short interest totalling 1,493,700 shares, an increase of 6.8% from the June 30th total of 1,398,400 shares. Based on an average daily trading volume, of 156,900 shares, the short-interest ratio is presently 9.5 days. Currently, 17.0% of the shares of the stock are short sold. View ANI Pharmaceuticals' Current Options Chain.
Who are some of ANI Pharmaceuticals' key competitors?
Some companies that are related to ANI Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), Evotec (EVTCY), Nektar Therapeutics (NKTR), Arrowhead Pharmaceuticals (ARWR), The Medicines (MDCO), HUTCHISON CHINA/S (HCM), Global Blood Therapeutics (GBT), PTC Therapeutics (PTCT), Arena Pharmaceuticals (ARNA), Genmab A/S (GMAB), Amicus Therapeutics (FOLD), Myokardia (MYOK) and Agios Pharmaceuticals (AGIO).
What other stocks do shareholders of ANI Pharmaceuticals own?
Who are ANI Pharmaceuticals' key executives?
ANI Pharmaceuticals' management team includes the folowing people:
- Mr. Arthur S. Przybyl, Pres, CEO & Director (Age 62)
- Mr. Stephen P. Carey, CFO & VP of Fin. (Age 48)
- Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 56)
- Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 47)
Who are ANI Pharmaceuticals' major shareholders?
ANI Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.82%), Vanguard Group Inc. (4.68%), Nomura Holdings Inc. (3.12%), Nomura Holdings Inc. (3.10%), First Manhattan Co. (2.44%) and Renaissance Technologies LLC (2.39%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer, Thomas Haughey and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals.
Which institutional investors are selling ANI Pharmaceuticals stock?
ANIP stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Weiss Asset Management LP, Charles Schwab Investment Management Inc., Cadence Capital Management LLC, Panagora Asset Management Inc., Skandinaviska Enskilda Banken AB publ , Phocas Financial Corp. and Phocas Financial Corp.. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, James G Marken, Meridian Venture Partners Ii L and Robert W Schrepfer. View Insider Buying and Selling for ANI Pharmaceuticals.
Which institutional investors are buying ANI Pharmaceuticals stock?
ANIP stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Nomura Holdings Inc., Nomura Holdings Inc., Renaissance Technologies LLC, Nuveen Asset Management LLC, BlackRock Inc., THB Asset Management and First Manhattan Co.. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash and Thomas Haughey. View Insider Buying and Selling for ANI Pharmaceuticals.
How do I buy shares of ANI Pharmaceuticals?
Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ANI Pharmaceuticals' stock price today?
One share of ANIP stock can currently be purchased for approximately $64.70.
How big of a company is ANI Pharmaceuticals?
ANI Pharmaceuticals has a market capitalization of $782.61 million and generates $201.58 million in revenue each year. The specialty pharmaceutical company earns $15.49 million in net income (profit) each year or $4.61 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.View Additional Information About ANI Pharmaceuticals.
What is ANI Pharmaceuticals' official website?
How can I contact ANI Pharmaceuticals?
ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]
MarketBeat Community Rating for ANI Pharmaceuticals (NASDAQ ANIP)
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
